artelo.jpg
Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss
February 02, 2023 09:00 ET | Artelo Biosciences
SOLANA BEACH, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
artelo.jpg
Artelo Biosciences to Present at Sequire Biotechnology Conference on February 2nd
January 26, 2023 08:30 ET | Artelo Biosciences
CEO Gregory Gorgas to discuss developments related to the Company’s Cancer Appetite Recovery Study (CAReS) Presentation on Thursday, February 2, 2023 at 1:00 PM ET SOLANA BEACH, Calif., Jan. 26,...
artelo.jpg
Artelo Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update
November 08, 2022 08:00 ET | Artelo Biosciences
Enrollment of Phase 2a CAReS Study Expected to Commence Near Year-End $19.5 Million in Cash and Investments as of September 30, 2022 SOLANA BEACH, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Artelo...
artelo.jpg
Artelo Biosciences to Present at the 2022 Ladenburg Thalmann Healthcare Conference on September 29th
September 22, 2022 09:00 ET | Artelo Biosciences
SOLANA BEACH, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
artelo.jpg
Artelo Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 07, 2022 08:30 ET | Artelo Biosciences
SOLANA BEACH, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
artelo.jpg
Artelo Biosciences Reports Positive Pre-Clinical Results with its Novel Inhibitor to Fatty Acid Binding Protein 5
August 16, 2022 09:00 ET | Artelo Biosciences
SOLANA BEACH, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
artelo.jpg
Artelo Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update
August 09, 2022 08:10 ET | Artelo Biosciences
CAReS Study Evaluating ART27.13 in Cancer Anorexia Progresses to Fourth Cohort ART26.12 Program to Target Chemotherapy-Induced Peripheral Neuropathy $21.3 Million in Cash and Investments as...
artelo.jpg
Artelo Biosciences Completes Enrollment of the First Three Cohorts in its CAReS Study Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss
July 19, 2022 09:07 ET | Artelo Biosciences
SOLANA BEACH, Calif., July 19, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
artelo.jpg
Artelo Biosciences Presents Positive Pre-Clinical Results of ART26.12, a Novel FABP5 Inhibitor, in Alleviating Chemotherapy-Induced Pain
June 27, 2022 08:30 ET | Artelo Biosciences
SOLANA BEACH, Calif., June 27, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
artelo.jpg
Artelo Biosciences Selected for Oral Presentation at the 32nd Annual ICRS Symposium in Galway, Ireland
June 24, 2022 08:30 ET | Artelo Biosciences
SOLANA BEACH, Calif., June 24, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...